Welcome to our dedicated page for Acumen Pharmaceuticals news (Ticker: ABOS), a resource for investors and traders seeking the latest updates and insights on Acumen Pharmaceuticals stock.
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease. Company updates consistently highlight progress in its Phase 2 ALTITUDE-AD trial, scientific presentations, collaborations and financial disclosures.
Visitors to this ABOS news page can review press releases on key clinical milestones, such as enrollment updates and the initiation of the open-label extension portion of ALTITUDE-AD, as well as data readouts from the Phase 1 INTERCEPT-AD study and subsequent analyses. Acumen also reports on operational innovations in trial execution, including the use of a plasma pTau217 assay to streamline screening and reduce costs in its Phase 2 program.
In addition to clinical trial developments, Acumen regularly announces scientific findings presented at major Alzheimer’s and neurology conferences. These items include data on sabirnetug’s selectivity for AβOs over monomeric amyloid beta, biomarker results, and research on Enhanced Brain Delivery (EBD™) approaches in collaboration with JCR Pharmaceuticals using transferrin-receptor-targeting, blood–brain barrier-penetrating technology.
Investors and followers of ABOS will also find news related to corporate events, such as board appointments, strategic collaboration agreements and quarterly financial results, which are often accompanied by conference call and webcast details. This page provides a centralized view of Acumen’s public communications as it advances its AβO-targeted therapeutic programs for Alzheimer’s disease.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced positive topline results from its Phase 1 study comparing subcutaneous (SC) and intravenous (IV) formulations of sabirnetug in healthy volunteers. The study demonstrated that weekly SC administration of sabirnetug was well-tolerated, with sufficient systemic exposure to support further clinical development.
The trial included 12 subjects receiving single IV doses of 2,800 mg and 16 subjects receiving four weekly SC doses of 1,200 mg. The most common adverse events were mild injection site reactions (62.5%), which all resolved. The SC formulation utilizes Halozyme's ENHANZE® drug delivery technology, enabling large volume SC injection with improved dispersion and absorption.
Sabirnetug, the first humanized monoclonal antibody showing selective target engagement of amyloid beta oligomers (AβOs) in Alzheimer's disease patients, is being developed as a more convenient administration option compared to IV treatment. The Phase 2 ALTITUDE-AD study of IV sabirnetug is currently ongoing.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced upcoming scientific presentations at two major conferences: the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) in Vienna from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego from April 5-9, 2025.
The presentations will highlight the implementation of a validated research-use plasma pTau217 assay in screening participants for the Phase 2 ALTITUDE-AD study of sabirnetug, their novel therapeutic targeting soluble amyloid beta oligomers (AβOs) for early symptomatic Alzheimer's disease treatment.
Key presentations include:
- Oral presentation on ALTITUDE-AD study at AD/PD on April 1
- Two poster presentations at AD/PD focusing on amyloid beta preparation and neuronal binding studies
- Oral presentation on plasma pTau217 screening at AAN on April 7
- Poster presentation on INTERCEPT-AD biomarker results at AAN on April 9
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in two upcoming investor conferences.
The company will engage in webcast fireside chats at:
- UBS Virtual CNS Day on March 17, 2025, at 12:30 p.m. ET
- Stifel Virtual CNS Days on March 18, 2025, at 3:30 p.m. ET
The webcasts will be accessible through the Investors section of Acumen's website (www.acumenpharm.com) and will remain available for 90 days after the events.
Acumen Pharmaceuticals (NASDAQ: ABOS) announced the publication of Phase 1 INTERCEPT-AD clinical trial results for sabirnetug (ACU193) in the Journal of Prevention of Alzheimer's Disease. The study, involving 65 early Alzheimer's disease patients, demonstrated that sabirnetug was generally well-tolerated with dose-dependent target engagement of amyloid beta oligomers (AβOs) and significant amyloid plaque reduction in higher dose cohorts.
Key findings include selective AβO target engagement, low overall levels of ARIA-E, and only one participant experiencing mild ARIA-E that resolved within four weeks. The company is currently conducting the Phase 2 ALTITUDE-AD trial, which began in May 2024 and aims to enroll approximately 540 adults across 75 sites in the U.S., Canada, EU, and U.K. Enrollment completion is expected in the first half of 2025.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 3:00 p.m. ET. Interested parties can access the live webcast through the Investors section of www.acumenpharm.com, where it will remain available for 90 days. The company specializes in developing novel therapeutics targeting toxic soluble amyloid beta oligomers.
Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q3 2024 financial results and business updates. The company expects to complete enrollment for its Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease in H1 2025. Cash position stands at $258.9 million as of September 30, 2024, expected to fund operations into H1 2027. Q3 financial results show R&D expenses increased to $27.2 million from $11.2 million year-over-year, while net loss widened to $29.8 million from $13.0 million. The company extended its collaboration with Lonza for potential commercial manufacturing of sabirnetug and appointed Amy Schacterle as Chief Regulatory Officer.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced its participation in the upcoming Stifel Healthcare Conference. The company's management will engage in a fireside chat on Monday, Nov. 18, 2024, at 11:30 a.m. ET. Acumen, a clinical-stage biopharmaceutical company, is developing a novel treatment targeting toxic soluble amyloid beta oligomers for Alzheimer's disease. The presentation will be accessible via live webcast on the company's website under the Investors tab and will remain available for 90 days following the event.
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced its upcoming participation in the UBS Global Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET). Acumen, a clinical-stage biopharmaceutical company, is developing a novel treatment targeting toxic soluble amyloid beta oligomers for Alzheimer's disease. The presentation will be accessible via live webcast on the company's website under the Investors tab and will remain available for 90 days.
Acumen Pharmaceuticals (NASDAQ: ABOS) has appointed Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality. Dr. Schacterle brings over 30 years of experience in regulatory affairs and quality assurance, with expertise in central nervous system diseases. She previously served as Senior VP of R&D Strategy at Sage Therapeutics, where she led regulatory efforts for the first postpartum depression treatment approval. She joins as the company advances its Alzheimer's disease therapeutic candidate, sabirnetug, which is currently in Phase 2 clinical trials across five countries. Dr. Schacterle replaces Dr. Janice Hitchcock, who is retiring after successfully leading the regulatory strategy for the Phase 1 INTERCEPT-AD study and Phase 2 ALTITUDE-AD study.
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, has scheduled its third quarter 2024 financial results release for November 12, 2024. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss business updates and financial performance. Interested participants must pre-register at least one day in advance to receive dial-in information.